First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

Memorial Sloan Kettering Cancer Center, New York

Fox Chase Cancer Center, Philadelphia

Sarah Cannon Research Institute, Nashville

Ohio State University, Columbus

Barbara Ann Karmanos Cancer Institute, Detroit

University of Kansas Medical Center Research Institute, Fairway

University of Oklahoma Stephenson Cancer Center, Oklahoma City

CTRC at the University of Texas Health Science Center, San Antonio

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston

Princess Margaret Hospital, Toronto

McGill University Health Centre, Montreal